The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
BACKGROUND
The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated.


METHODS
An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.


CONCLUSIONS
Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.
Kesterson
Joshua P
JP
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Mhawech-Fauceglia
Paulette
P
Lele
Shashikant
S
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy; D000068258:Bevacizumab; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel